Global Rituximab Biosimilar Market 2027: Top Key Players Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co.,Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries Ltd., Intas Biopharmaceuticals Ltd., C.H. Boehri

Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United States it marketed as Rituxan by Genentech in partnership with Biogen Idec. In Japan it is marketed by Chugai and Zenyaku Kogyo Co. Ltd. It is approved in the U.S. in 1997 and by European Medical Agency in June 1998. Rituximab is one of the top selling pharmaceutical product of Roche Holding AG. Therefor many biosimilar pharmaceutical companies are focusing on product development of rituximab biosimilar to compel the biosimilar product market share. Some of the market players leading the global rituximab biosimilar market include Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co.,Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries Ltd., Intas Biopharmaceuticals Ltd., C.H. Boehringer Sohn AG & Ko. KG, and BioXpress Therapeutics SA.

Request For Sample @ https://bit.ly/2SYX06k

The rituximab biosimilar market is expected to grow at higher pace during forecast period, since the rituximab is one of the best seller drug product that accounts for around 2.1 million prescriptions worldwide since the market launch. In addition, rituximab has lost its patent in the United States and Europe in 2016 and 2013 respectively. Presence of strong pipeline products such as ABP 789, MabTas, Reditux, and JHL 101, increasing incidence of chronic disease (such as cancer, arthritis, and diabetes) are the other factor that boos the demand for the rituximab biosimilar market. Furthermore, rising demand for biosimilar drugs and entry of new pharmaceutical market players have boosted the growth of the rituximab biosimilar market during the forecast period. However, stringent regulatory approval process for the rituximab biosimilar is major restraining factor that hampers the growth of the rituximab biosimilar market. In addition, IP strategies used by the product innovator companies to fight against the biosimilar competition, such as advancement in original formulation or screening for some new indications restrain the growth of the rituximab biosimilar market. For instance, Roche announced the development of new formulation for Rituxan as strategy to fight against biosimilar competition.

Based on application, the global rituximab biosimilar market is segmented in non-Hodgkin’s lymphoma, chronic lymhocytic leukemia, rheumatoid arthritis and others. Other indication includes off-label use such as thrombocytopenia, macroglobulinemia, immune thrombocytopenic purpura, Burkitt lymphoma, autoimmune hemolytic anemia, and multiple sclerosis. Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia segment are expected to grow at rapid pace during the forecast period owing to increasing incidence and prevalence rate of chronic disease. Based on distribution channel the global rituximab biosimilar market is segmented as hospital pharmacy, online pharmacy, retail pharmacy and others. Hospital pharmacy segment is expected to grow during forecast period due to increase in number of hospital visit and hospital stays for the treatment of different chronic disease.

At geographic level segmentation, the global rituximab biosimilar market has been categorized into Europe, Asia Pacific, North America, Latin America and Middle East & Africa. In terms of revenue, Europe is major contributor for the global rituximab biosimilar market. Europe is the major contributor to the global market owing to the loss of a rituximab patent in 2013. In June 2017, Sandoz announce the launch of first rituximab biosimilar in Europe.

Request For Table Of Content (TOC) @ https://bit.ly/2SYX06k

Europe is followed by North America which is second major revenue generator during the forecast period. The growth of the rituximab biosimilar market in North America is owing to factors such as strong clinical trial/product pipeline, increasing research and drug development activities propels rituximab biosimilar market growth in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.